Clinical Trials Logo

Metastatic Breast Cancer clinical trials

View clinical trials related to Metastatic Breast Cancer.

Filter by:

NCT ID: NCT05090358 Active, not recruiting - Breast Cancer Clinical Trials

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Start date: October 8, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study to find out whether a very low carbohydrate diet (ketogenic diet), a low carbohydrate diet, or the study drug canagliflozin can prevent high blood sugar and may improve the effectiveness of cancer therapy in people who are receiving standard treatment with alpelisib and fulvestrant for their metastatic PIK3CA-mutant breast cancer.

NCT ID: NCT05086731 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer

Start date: October 22, 2021
Phase: N/A
Study type: Interventional

This clinical trial evaluates the feasibility and acceptability of a mobile health device in improving oral chemotherapy adherence in women with triple negative breast cancer that has not spread to other places in the body (non-metastatic). A mobile health device, called SMRxT smart pill bottle may help doctors to remind patients to take medicine on time and monitor their symptoms.

NCT ID: NCT05002868 Active, not recruiting - Solid Tumor Clinical Trials

Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors

Start date: October 5, 2021
Phase: Phase 1
Study type: Interventional

An open-label, two-part Phase I/Ib study of RP12146 in adult patients with locally advanced or metastatic solid tumors. The first part (Part 1) is a Phase I dose-escalation, 3+3 design, open-label, MTD determination study and will enroll patients who have tumors known to harbour DNA repair deficiencies. The second part (Part 2) is a Phase Ib, dose-expansion at the MTD (or optimal dose) and will enroll patients with a confirmed deleterious HRR mutation in their tumor as identified by a central genomics testing laboratory.

NCT ID: NCT04740918 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

KATE3
Start date: June 7, 2021
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety and patient-reported outcomes of trastuzumab emtansine plus atezolizumab compared with trastuzumab emtansine plus placebo in participants with HER2-positive and PD-L1-positive LABC or MBC.Participants must have progressed either during or after prior trastuzumab- (+/- pertuzumab) and taxane-based therapy for LABC/MBC; or during (or within 6 months after completing) trastuzumab- (+/-pertuzumab) and taxane-based therapy in the neoadjuvant and/or adjuvant setting.

NCT ID: NCT04734262 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

SPARK
Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of sitravatinib plus tislelizumab or combination with nab-paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC) patients.

NCT ID: NCT04733417 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Start date: May 26, 2021
Phase: Phase 2
Study type: Interventional

The study is being conducted to assess the efficacy and safety of SHR6390 combined with famitinib in the treatment of advanced or metastatic breast cancer that progress in 1-2 line endocrine therapy.

NCT ID: NCT04708860 Active, not recruiting - Breast Cancer Clinical Trials

Feasibility of Fasting & Exercise in Pts With HR+ MBC

Start date: January 15, 2021
Phase: N/A
Study type: Interventional

This research is evaluating the impact of a 12-week prolonged nightly fasting (POF) and exercise intervention on metabolic markers and patient reported outcomes in women with metastatic breast cancer (MBC) initiating endocrine therapy in combination with palbociclib or alpelisib.

NCT ID: NCT04639986 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Start date: November 23, 2020
Phase: Phase 3
Study type: Interventional

The goal of this study is to compare the study drug, sacituzumab govitecan-hziy, versus doctors' treatment of choice in participants with HR+/HER2- metastatic breast cancer (MBC) who have failed at least 2 prior chemotherapy regimens.

NCT ID: NCT04556773 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

DB-08
Start date: December 17, 2020
Phase: Phase 1
Study type: Interventional

DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer

NCT ID: NCT04538742 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

DB-07
Start date: December 28, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer